» Articles » PMID: 20304245

Comparative Demographics of the European Cystic Fibrosis Population: a Cross-sectional Database Analysis

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 2010 Mar 23
PMID 20304245
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Country-specific patients' registries are rarely used to make international comparisons because of protocol discrepancies in data collation. We present data from a European cystic fibrosis registry that is dedicated to collection of demographic data, and assess whether the resources available in countries with and without European Union (EU) membership affects care and survival of patients.

Methods: Data for demographic indicators-age, age at diagnosis, sex, and genotype-for patients with cystic fibrosis from 35 European countries were combined, and used to establish the differences in demographic indicators between EU and non-EU countries. EU membership status in 2003 was used to divide countries. We modelled demographic indicators of EU countries on non-EU countries to estimate the size of the cystic fibrosis population if non-EU countries had had the same resources available for patients as did EU countries.

Findings: Data were gathered for 29 025 patients, who had a median age of 16.3 years (IQR 8.9-24.8), with a difference of 4.9 years (95% CI 4.4-5.1; p<0.0001) between EU (median 17.0 years, IQR 9.5-25.6) and non-EU countries (12.1 years, 6.0-19.2). The proportion of patients older than 40 years was higher in EU countries (1205 [5%]) than in non-EU countries (76 [2%]), with an odds ratio of 2.4 (95% CI 1.9-3.0, p<0.0001). We estimated that the cystic fibrosis population in non-EU countries would increase by 84% if patients had a demographic profile comparable to that of patients in EU countries.

Interpretation: Future studies need to establish the reasons for the lower proportion of patients with cystic fibrosis in non-EU countries than in EU countries, such as underdiagnosis and premature childhood mortality.

Funding: European Community's Sixth Framework Programme for Research, and Czech Ministry of Health.

Citing Articles

Prebiotics for people with cystic fibrosis.

Williams N, Jayaratnasingam J, Prayle A, Nevitt S, Smyth A Cochrane Database Syst Rev. 2023; 9:CD015236.

PMID: 37753791 PMC: 10523429. DOI: 10.1002/14651858.CD015236.pub2.


Clinical characteristics and genetic mutations of 10 Chinese children with cystic fibrosis or cystic frbrosis transmembrane conductance regulator-related disorders.

Tan S, Cao L Chin Med J (Engl). 2023; 137(14):1753-1755.

PMID: 37678334 PMC: 11268803. DOI: 10.1097/CM9.0000000000002834.


Risk factors for forced expiratory volume in 1 s decline in European patients with cystic fibrosis: data from the European Cystic Fibrosis Society Patient Registry.

Hatziagorou E, Fieuws S, Orenti A, Naehrlich L, Krivec U, Mei-Zahav M ERJ Open Res. 2023; 9(3).

PMID: 37483280 PMC: 10359040. DOI: 10.1183/23120541.00449-2022.


Multicenter Surveillance of Cystic Fibrosis in Korean Children.

Kim H, Hong S, Ahn K, Suh D, Noh S, Kim S Allergy Asthma Immunol Res. 2022; 14(5):494-504.

PMID: 36174992 PMC: 9523417. DOI: 10.4168/aair.2022.14.5.494.


MicroRNA global profiling in cystic fibrosis cell lines reveals dysregulated pathways related with inflammation, cancer, growth, glucose and lipid metabolism, and fertility: an exploratory study.

Catellani C, Cirillo F, Graziano S, Montanini L, Marmiroli N, Gulli M Acta Biomed. 2022; 93(3):e2022133.

PMID: 35775757 PMC: 9335447. DOI: 10.23750/abm.v93i3.12842.